Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of “Buy” from Analysts

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) has received a consensus rating of “Buy” from the seven analysts that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $63.67.

Several brokerages have recently commented on TARS. Guggenheim reissued a “buy” rating and set a $78.00 price objective (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. Oppenheimer boosted their price target on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 22nd. Barclays lowered their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. Jefferies Financial Group upped their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Finally, HC Wainwright reissued a “buy” rating and issued a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 26th.

Tarsus Pharmaceuticals Stock Up 5.3 %

TARS opened at $51.49 on Thursday. The firm has a market capitalization of $1.98 billion, a P/E ratio of -13.51 and a beta of 1.05. Tarsus Pharmaceuticals has a one year low of $20.08 and a one year high of $57.28. The company has a fifty day moving average price of $49.21 and a 200-day moving average price of $46.48. The company has a debt-to-equity ratio of 0.30, a current ratio of 5.42 and a quick ratio of 5.38.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its earnings results on Tuesday, February 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.68) by $0.08. The business had revenue of $66.41 million during the quarter, compared to analysts’ expectations of $58.80 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. Equities research analysts expect that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current fiscal year.

Insider Activity at Tarsus Pharmaceuticals

In related news, General Counsel Bryan Wahl sold 3,084 shares of the stock in a transaction dated Thursday, March 20th. The stock was sold at an average price of $50.11, for a total transaction of $154,539.24. Following the completion of the sale, the general counsel now directly owns 51,712 shares in the company, valued at $2,591,288.32. This represents a 5.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Dianne C. Whitfield sold 2,315 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the transaction, the insider now directly owns 50,751 shares in the company, valued at $2,349,263.79. This trade represents a 4.36 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 32,542 shares of company stock valued at $1,581,173. Insiders own 8.25% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in TARS. Toronto Dominion Bank purchased a new position in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $105,714,000. GF Fund Management CO. LTD. bought a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter worth about $44,000. Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. purchased a new position in Tarsus Pharmaceuticals during the 4th quarter valued at about $3,278,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in Tarsus Pharmaceuticals by 18.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 69,826 shares of the company’s stock valued at $3,866,000 after purchasing an additional 10,991 shares during the last quarter. Finally, Woodline Partners LP lifted its holdings in Tarsus Pharmaceuticals by 52.3% in the 4th quarter. Woodline Partners LP now owns 108,986 shares of the company’s stock worth $6,035,000 after buying an additional 37,417 shares during the period. 90.01% of the stock is currently owned by institutional investors.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.